Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01849952 |
Recruitment Status :
Recruiting
First Posted : May 9, 2013
Last Update Posted : October 4, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Astrocytoma Oligodendroglioma Oligoastrocytoma Anaplastic Astrocytoma Anaplastic Oligodendroglioma Anaplastic Oligoastrocytoma Glioblastoma Brain Tumors Brain Cancer |
Study Type : | Observational |
Estimated Enrollment : | 200 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas |
Actual Study Start Date : | February 28, 2020 |
Estimated Primary Completion Date : | May 2024 |
Estimated Study Completion Date : | May 2024 |
- Overall Survival [ Time Frame: 24 months ]Patients will be followed for survival every 12 weeks +/- 1 week.
- Progression-Free Survival [ Time Frame: 24 Months ]
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion/Exclusion Criteria:
- 18 years of age
- Brain tumor(s) to be resected for clinical reasons.
- Histological pathology confirmation that tumor is of glial origin, WHO Grade II, III or IV.
- Adequate tissue available for processing as determined by Pathology.
- Adequate decision making ability to review, discuss and sign a consent form to allow their tumor samples to be used for future human brain tumor biology laboratory research. Determination of capacity to consent is made by one of the co-investigators based on clinical assessment.
- Patients opting for the standard treatment regimen for their disease as well as ongoing clinical trials will be are eligible to participate in this study. Standard care for newly-diagnosed glioblastomas typically consists of surgical resection followed by radiotherapy with concomitant temozolomide, followed by adjuvant temozolomide chemotherapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01849952
Contact: Charlotte Esancy | 6036530619 | charlotte.a.esancy@hitchcock.org |
United States, Massachusetts | |
Tufts Medical Center | Active, not recruiting |
Boston, Massachusetts, United States, 02111 | |
Massachusetts General Hospital | Active, not recruiting |
Boston, Massachusetts, United States, 02114 | |
United States, New Hampshire | |
Dartmouth-Hitchcock Medical Center | Recruiting |
Lebanon, New Hampshire, United States, 03756 | |
Contact: Cancer Research Nurse 800-639-6918 cancer.research.nurse@dartmouth.edu | |
Principal Investigator: Arti B Gaur, PhD | |
Principal Investigator: Linton T Evans, MD | |
United States, Vermont | |
University of Vermont | Active, not recruiting |
Burlington, Vermont, United States, 05405 |
Principal Investigator: | Arti B Gaur, PhD | Dartmouth-Hitchcock Medical Center |
Publications:
Responsible Party: | Arti Gaur, PhD, Dartmouth-Hitchcock Medical Center |
ClinicalTrials.gov Identifier: | NCT01849952 |
Other Study ID Numbers: |
D12160 |
First Posted: | May 9, 2013 Key Record Dates |
Last Update Posted: | October 4, 2023 |
Last Verified: | October 2023 |
glioblastoma miRNA GBM astrocytoma |
Glioblastoma Brain Neoplasms Astrocytoma Oligodendroglioma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type |
Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Brain Diseases Central Nervous System Diseases Nervous System Diseases |